直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
    • AI + Finnegan
    • Appeals, Issues, and Legal Strategy
    • Diligence, Licensing, and Opinions
    • Global IP Enforcement, Litigation, and Trials
    • Patent Office Invalidation Proceedings
    • Prosecution and Portfolio Management
    • Trademark and Brand Management
    • AI, Electronics, and Information Technology
    • Chemicals, Industrials, and Materials
    • Communications
    • Consumer Goods and Services
    • Energy
    • Hospitality, Gaming, and Leisure
    • Life Sciences
    • Transportation and Logistics
  • Experience

生物技術

About

生物技術 業務的一部分 生命科學.

生物技術之智財保護的前導

50多年的執業中,Finnegan飛翰與生技領域的先驅廠商合作,制訂與執行成功的智財策略,包括就突破性進步取得專利,透過訴訟實施專利權,以及針對他人侵權與所有權的指控作辯護。我們代表禮來公司,在世界首推的生物科技產品(人工胰島素) 的訴訟案獲得勝訴,並且就一系列的生物技術提供諮詢或訴訟的服務,像是DNA自動定序,桃莉羊的複製,檢測胚胎染色體數異常的非侵入性方法,以及抗體平台設計。

了解法律,科學,和技術

強健的智財保護對於生技產業的推動是不可或缺的,並且依舊為其持續發展的關鍵。身為由科學家和生物技術工程師組成的智財權律師事務所,Finnegan期許能與科技的快速發展,和這個跨領域產業中不斷變化的法律議題齊頭並進。

隨著生技領域客戶以我們尚未想到的方式取得振奮人心的突破,我們透過以下方式提供協助:

  • 在地院和上訴法院,由經驗豐富的審判和上訴團隊,處理高價值產品的訴訟案
  • 高價值產品與技術之專利申請的擬稿與答辯
  • 評估圍繞著許多新科技且密集的專利叢林,並提供導引
  • 撰寫意見書,並就新技術和現有技術持續提供諮詢服務
  • 針對複雜的專利干擾、再審查程序、與核准後複審程序,主張及捍衛客戶的權益
  • 對合併、收購、授權、和結盟合作的可能性進行盡職調查
  • 智財授權合約的建構,起草,和談判
  • 提供商標起訴和諮詢服務

我們在既有和新興領域與客戶合作,包括:

  • 抗體療法
  • 分析/測定(法)之開發
  • 癌症治療 
  • CRISPR技術
  • 基因治療
  • 基因工程
  • 次世代定序平台
  • 重組生長因子
  • 合成生物學
  • 疫苗

保護創新之全面的法律,技術,和策略經驗

我們的生命科學業務由250多位律師和專業人士組成,致力於滿足客戶對於智財權服務的需求。多數擁有與生物學,化學,生物化學,醫學,藥理學,或生醫工程等相關學科的高階學位。大多具有紮實的研究和/或產業經驗,許多人在產業或大學任職,或在美國專利商標局擔任審查委員後加入Finnegan飛翰。

Everyone in this industry

Experience

Utility and design patent applications for brain machine interface company

Finnegan represents BrainCo, a developer of brain-machine interface (BMI) wearables that combine electroencephalography (EEG) signal processing with artificial intelligence (AI) and machine learning (ML) to enable users to control electronic devices using brain signals. The firm works with BrainCo to develop and implement its intellectual property strategy, including drafting and prosecuting utility and design patent applications, in support of the company’s efforts to build a robust patent portfolio covering innovations and designs related to BMI technologies used in toys, smart home appliances, and robotic devices.

Genzyme Corporation v. Sarepta Therapeutics, Inc. et al.

Representing Sarepta in defensive patent litigation involving Elevidys®, a one-time gene therapy for the treatment of a neuromuscular disease known as Duchenne muscular dystrophy (DMD) and in parallel offensive inter partes reviews (IPRs).

1:24-cv-00882, D. Del., Judge Andrews

Merck Sharp & Dohme LLC v. Hetero USA Inc., Lupin Limited et al.
Representing Merck in Hatch-Waxman litigation involving the HIV drugs ISENTRESS® and ISENTRESS® HD.

2:23-cv-00094, 2:23-cv-02364, D.N.J., Judges Cecchi, Padin, Wettre

Pioneer Hi-Bred International, Inc. et al. v. Syngenta Seeds, LLC

Representing plaintiff Pioneer in a district court patent infringement litigation involving methods for producing doubled haploid maize plants.

1:22-cv-01280, D. Del.

Bayer Cropscience LP et al. v. Corteva Agriscience LLC et al.
Representing defendant Corteva in a Delaware state court action for breach of contract arising out of a patent cross-license agreement relating to Agrobacterium-mediated plant transformation and transgenic seeds.

N22C-07-168, Delaware Superior Court, Complex Commercial Litigation Division

Corteva Agriscience LLC v. Monsanto Company et al.

Representing plaintiff Corteva Agriscience in a district court patent infringement litigation involving transgenic plants and plant cells that produce enzymes conferring herbicide resistance.

1:22-cv-01046, D. Del., Judge Williams

More

Insights

Conference

2026 China Pharmaceutical Innovation Conference

July 22-24, 2026

Shanghai

Conference

7th International Conference on Biofuels and Bioenergy

June 25-26, 2026

Edinburgh

European IP Blog

UPC Central Division Revokes Patent Covering Covid-19 Treatment Remdesivir

8 June 2026

Conference

BIA Start-up Festival

May 21, 2026

London

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Conference

2026 Advanced Chemical & Biotech Patent Institute

May 11-12, 2026

San Francisco

More

Upcoming Events

Conference

2026 China Pharmaceutical Innovation Conference

July 22-24, 2026

Shanghai

News

Media Mention

Finnegan Hires Kirkland & Ellis Litigator for London Office

June 8, 2026

Commentary

Finnegan Hires Kirkland Partner as It Eyes UK Growth

June 8, 2026

Press Release

London-Based Life Sciences Litigator Jin Ooi Bolsters Finnegan’s Global IP Litigation Capabilities

June 8, 2026

Award/Ranking

Finnegan Partner Antje Brambrink Shortlisted for Women in Business Law EMEA Award

May 13, 2026

Commentary

Justices to Side with Generic Drugmakers in Patent Spat, Attorneys Predict

May 5, 2026

Award/Ranking

Finnegan Wins IP Firm of the Year at the 2026 LSPN Awards

May 1, 2026

More

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP